<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529294</url>
  </required_header>
  <id_info>
    <org_study_id>CILO522D2401</org_study_id>
    <nct_id>NCT01529294</nct_id>
  </id_info>
  <brief_title>Single-dose Iloperidone Pharmacokinetics in Patients With Mild or Moderate Liver Disease, Compared to Healthy Volunteers</brief_title>
  <official_title>Open-label, Single-dose, Parallel-group Study to Compare the PKs of Iloperidone in Subjects With Mild or Moderate Hepatic Impairment With That in Matched Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study aims to determine the pharmacokinetic profile and the tolerability of iloperidone
      in subjects with mild or moderate hepatic impairment comparatively to healthy matched
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure: Area Under Curve (AUClast, AUCinf) and maximum concentration (Cmax)</measure>
    <time_frame>predose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 and 120 hours post-dose</time_frame>
    <description>Pharmacokinetics of iloperidone in subjects with mild or moderate hepatic impairment, compared to healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration following drug administration (Cmax) of iloperidone</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose, and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood and urine samples will be collected and plasma and urine concentration will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protein binding of iloperidone</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose, and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood samples will be collected and protein binding will be measured .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time Curve from time zero to infinity (AUCinf) of iloperidone</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose, and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood and urine samples will be collected and plasma and urine concentration will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the plasma Curve (AUC) of iloperidone metabolite P88</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood and urine samples will be collected and plasma and urine concentrations of metabolite 88 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time Curve from time zero to infinity (AUCinf) of iloperidone metabolite P88 records, listed by subject. Summary statistics provided by impairment group and visit/time.</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood and urine samples will be collected and plasma and urine concentrations of metabolite 88 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration following drug administration (Cmax) of iloperidone metabolites P88</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood and urine samples will be collected and plasma and urine concentrations of metabolite 88 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein binding of iloperidone metabolites P88 (CLr)</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood samples will be collected and protein binding of metabolite 88 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the plasma Curve (AUC) of iloperidone metabolite P95</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood and urine samples will be collected and plasma and urine concentrations of metabolite 95 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time Curve from time zero to infinity (AUCinf) of iloperidone metabolite P95</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood and urine samples will be collected and plasma and urine concentrations of metabolite 95 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration following drug administration (Cmax) of iloperidone metabolites P95</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood and urine samples will be collected and plasma and urine concentrations of metabolite 95 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein binding of iloperidone metabolites P95</measure>
    <time_frame>pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120 hours post-dose and from pre-dose to 48 hours post-dose</time_frame>
    <description>Blood samples will be collected and protein binding of metabolite 95 will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Day 6</time_frame>
    <description>Adverse events will be determined by evaluating clinical, laboratory evaluations, impact on vital signs and impacts on Electrocardiograms (ECGs)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Iloperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects receive a single oral dose of 2 mg iloperidone as a tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloperidone</intervention_name>
    <arm_group_label>Iloperidone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria (all subjects):

          -  Caucasian subjects

          -  Inclusion criteria (hepatic impaired subjects):

          -  subjects with physical signs consistent with a clinical diagnosis of stable liver
             disease, which has been confirmed by imaging techniques, ultrasound, Magnetic
             Resonance Imaging or Computed Tomogram within 3 months of screening, and a creatinine
             clearance &gt; 50 mL/min (based on Cockroft and Gault formula).

          -  Inclusion criteria (healthy volunteers):

          -  good general health

          -  matched by age, gender, smoking status, Body Mass Index, and CYP2D6 phenotype to
             hepatic impaired subjects.

        Exclusion Criteria:

          -  Exclusion criteria (all subjects):

          -  Subjects who report smoking a pipe, cigars or more than 20 cigarettes per day .

          -  History of drug abuse as defined in Diagnostic and Statistical Manual of Mental
             Disorders, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior
             to screening

          -  History of first-dose response/syncope to alpha1-blocking agents

          -  Exclusion criteria (Hepatic impaired subjects):

          -  Patients with symptoms or 6 months past history of encephalopathy.

          -  Patients with clinical evidence of moderate-severe ascites.

          -  Patients having a previous surgical porto-systemic shunt.

          -  Exclusion criteria (Healthy volunteers):

          -  History of alcohol abuse prior to dosing, or evidence of such abuse during screening.

          -  Pulse Rate &gt; 200 msec

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic impairment</keyword>
  <keyword>Iloperidone</keyword>
  <keyword>ILO522D</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

